



LKT Laboratories, Inc.

VX-702

Phone: 888-558-5227

651-644-8424

Fax: 888-558-7329

Email: getinfo@lktlabs.com

Web: lktlabs.com

Product Information

Product ID V9202

CAS No. 479543-46-9

Chemical Name

Synonym VX702

Formula $C_{19}H_{12}F_4N_4O_2$

Formula Wt. 404.32

Melting Point

Purity $\geq 98\%$

Solubility DMSO 81 mg/mL (200.34 mM)


Water Insoluble

Ethanol Insoluble

Store Temp $-20^{\circ}C$

Ship Temp Ambient

Description VX-702 inhibits p38 MAPK, preventing p38 MAPK-dependent inflammatory cytokine release. VX-702 is in development to treat inflammation and cardiovascular diseases and currently shows mixed results in clinical trials as a potential treatment for rheumatoid arthritis. In vitro, VX-702 decreases platelet lesioning in storage without affecting platelet function.



Bulk quantities available upon request

Product ID	Size
------------	------

V9202	5 mg
-------	------

V9202	25 mg
-------	-------

V9202	100 mg
-------	--------

References Skripchenko A, Awatefe H, Thompson-Montgomery D, et al. An inhibition of p38 mitogen activated protein kinase delays the platelet storage lesion. PLoS One. 2013 Aug 13;8(8):e70732. PMID: 23967093.

Ding C. Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome. Curr Opin Investig Drugs. 2006 Nov;7(11):1020-5. PMID: 17117592.

Lee MR, Dominguez C. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein. Curr Med Chem. 2005;12(25):2979-94. PMID: 16378500.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.